Trials Sponsors Conditions Drugs Pricing

Conditions

Graft Versus Host Disease Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases

Keywords

graft versus host diseaseadult acute myeloid leukemia in remissionadult acute myeloid leukemia with 11q23 (MLL) abnormalitiesadult acute myeloid leukemia with inv(16)(p13;q22)adult acute myeloid leukemia with t(15;17)(q22;q12)adult acute myeloid leukemia with t(16;16)(p13;q22)adult acute myeloid leukemia with t(8;21)(q22;q22)recurrent adult acute myeloid leukemiarecurrent childhood acute myeloid leukemiachildhood acute myeloid leukemia in remissionadult acute lymphoblastic leukemia in remissionrecurrent adult acute lymphoblastic leukemiachildhood acute lymphoblastic leukemia in remissionrecurrent childhood acute lymphoblastic leukemiaaccelerated phase chronic myelogenous leukemiablastic phase chronic myelogenous leukemiachildhood chronic myelogenous leukemiachronic phase chronic myelogenous leukemiarelapsing chronic myelogenous leukemiasecondary acute myeloid leukemiade novo myelodysplastic syndromespreviously treated myelodysplastic syndromes

Outcome Measures

Primary Outcomes (1)

Incidence of graft-vs-host disease or graft failure

Interventions

graft versus host disease prophylaxis/therapyBiological

allogeneic bone marrow transplantationProcedure

in vitro-treated bone marrow transplantationProcedure

Eligibility Criteria

AgeUp to 65 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following hematologic malignancies or genetic disorders: * Acute myeloid leukemia (AML), meeting 1 of the following criteria * Primary resistant disease * Disease in complete remission (CR) * Disease in first early relapse * Secondary AML arising out of myelodysplastic syndrome * Acute lymphocytic leukemia (ALL), meeting 1 of the following criteria: * Primary resistant disease * Disease in CR * Disease in first early relapse * Chronic myelogenous leukemia * Myelodysplastic syndrome (MDS) * Chronic myelomonocytic leukemia * Philadelphia chromosome-negative myeloproliferative disorder * Multiple myeloma * Hodgkin's lymphoma * Non-Hodgkin's lymphoma * Genetic disorders or inborn errors of metabolism * Planning allogeneic bone marrow transplantation at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Medical Center * Must have an HLA-identical sibling donor by serologic or molecular typing of HLA class I antigens and molecular typing of HLA class II antigens PATIENT CHARACTERISTICS: Performance status * Not specified Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Not specified Renal * Not specified PRIOR CONCURRENT THERAPY: Biologic therapy * No prior red blood cell or platelet transfusion from the same donor Other * Concurrent participation in another clinical trial allowed

Sponsors & Collaborators

National Cancer Institute (NCI)
NIHcollaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Otherlead

Study Sites (1)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21231-2410, United States

MeSH Terms

Conditions

Graft vs Host DiseaseLeukemiaLymphomaMultiple MyelomaNeoplasms, Plasma CellMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative DiseasesCongenital AbnormalitiesLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, Accelerated PhaseBlast CrisisLeukemia, Myeloid, Chronic-PhaseLeukemia, Myelomonocytic, ChronicLeukemia, Myelomonocytic, JuvenileLeukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Study Officials

Richard J. Jones, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PRINCIPAL INVESTIGATOR

Enrollment

72 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Sponsor Type: OTHER

Study Record Dates

First Submitted

December 14, 2005

First Posted

December 15, 2005

Study Start

December 2002

Date type not reported

This date has not been verified as actual or estimated.

Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Study Officials

Enrollment

Study Design

Study Record Dates

Interventions

Condition Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Study Officials

Enrollment

Study Design

Study Record Dates

Interventions

Condition Hierarchy (Ancestors)

Source record

Locations